Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.
- Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.
- The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023.
- Third Quarter 2023 Financial Update:
Avalo had $10.2 million in cash and cash equivalents as of September 30, 2023. - The Company raised $46.2 million of net proceeds from equity financings in the nine months ended September 30, 2023.